Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation

University Hospital-USP, Brazil
Vaccine (Impact Factor: 3.62). 06/2013; 31(51). DOI: 10.1016/j.vaccine.2013.05.042
Source: PubMed


The ten-pneumococcal conjugate vaccine (PCV10) was introduced into the national immunization program for childhood vaccination schedules by the Brazilian Health Public Service in March 2010. The aim of this study was to compare Streptococcus pneumoniae serotype distribution, antibiotic resistance patterns, and potential coverage before (January 2006-June 2010) and after (July 2010-September 2012) PCV10 introduction. The incidence of invasive pneumococcal disease (IPD), patient demographics, and disease characteristics were recorded. This study was conducted at the University Hospital of Sao Paulo University in Brazil from January 2006 to September 2012. Serotyping was performed using multiplex PCR typing, and antimicrobial sensitivity by Clinical and Laboratory Standards Institute (CLSI). A total of 259 S. pneumoniae strains were isolated from patients with IPD. The ages of the patients ranged from 3 months to 95 years old. The strains were isolated from cerebrospinal fluid, pleural fluid, and blood. The incidence of IPD among patients at HU-USP changed after the introduction of PCV10. The overall incidence of IPD was 3.42 cases per 1000 admissions in the vaccine pre- implementation period and of 2.99 cases per 1000 admissions in the vaccine post-implementation period. The incidence of IPD among children<2 y.o. attended at HU-USP changed significantly after the introduction of PCV10, from 20.30 to 3.97 of incidence. The incidence of PCV10- serotypes decrease from 16.47 to 0.44 in the same age, before and after PC10 implementation, respectively. Moreover, it was possible to realize the sensitivity to penicillin among isolates increased significantly in the post-vaccine period. Data from this study suggest that PCV10 contributed to decrease with PID rate among children less than 2 y.o. The resistance rate among pneumococcal isolates also could be observed since serotypes with greater resistance to beta lactam antibiotics were not easily isolated after vaccination.

Download full-text


Available from: Alfredo Gilio, Mar 17, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Advisory Committee on Vaccines of the Spanish Association of Paediatrics upda-tes the immunisation schedule every year, taking into account epidemiological data as wellas evidence on the safety, effectiveness and efficiency of current vaccines, including levelsof recommendation. In our opinion, this is the optimal vaccination calendar for all childrenresident in Spain.Regarding the vaccines included in the official unified immunization schedule, the Committeeemphasizes the administration of the first dose of hepatitis B either at birth or at 2 months oflife; the recommendation of the first dose of MMR and varicella vaccine at the age of 12 months, with the second dose at the age of 2-3 years; DTaP or Tdap vaccine at the age of 6 years, followed by another Tdap booster dose at 11-12 years old; Tdap strategies for pregnant womenand household contacts of the newborn, and immunization against human papillomavirus ingirls aged 11-12 years old with a 2 dose scheme (0, 6 months).The Committee reasserts its recommendation to include vaccination against pneumococcaldisease in the routine immunisation schedule, the same as it is being conducted in WesternEuropean countries.The recently authorised meningococcal B vaccine, currently blocked in Spain, exhibits theprofile of a universal vaccine. The Committe insists on the need of having the vaccine availablein communitary pharmacies.It has also proposed the free availability of varicella vaccines. Their efectiveness and safetyhave been confirmed when they are administred from the second year of life. Vaccinationagainst rotavirus is recommended in all infants. The Committee stresses the need to vaccinatepopulation groups considered at risk against influenza and hepatitis A. © 2013 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.
    Anales de Pediatría 11/2012; 82(1). DOI:10.1016/j.anpedi.2012.10.002 · 0.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives To evaluate the susceptibility patterns among Streptococcus pneumoniae recovered during the years 2010–2012 and to correlate these with serotypes. Methods Pneumococci from invasive sites were serotyped by sequential multiplex PCR and/or Quellung reaction. Etest strips were used to determine the minimal inhibitory concentrations, and the Clinical and Laboratory Standards Institute (CLSI) guidelines were used for interpretation. Genetic determinants of macrolide resistance were assessed by PCR, and the occurrence of the D phenotype was analyzed following the recommendations of the CLSI. Results One hundred fifty-nine S. pneumoniae were studied; most were recovered from blood and were associated with serotypes 14, 3, 4, 23F, 20, 7F, 12F, 19A, and 19F. Pneumococcal conjugate vaccine PCV7, PCV10, and PCV13 and 23-valent polysaccharide vaccine serotypes represented 38.2%, 48.7%, 64.5%, and 85.5%, respectively. β-Lactam non-susceptibility (non-meningitis) was basically related to serotype 19A. For meningitis, it was observed in 21.4% (serotypes 14, 3, 9 V, 23F, and 24F). Resistance to erythromycin occurred in (8.2%) and mefA was the most common macrolide genetic determinant. One isolate was resistant to levofloxacin. Non-susceptibility to trimethoprim–sulfamethoxazole was 37.7% and to tetracycline was 22.0%. Conclusions Our population of pneumococci represents a transition era, soon after the introduction of PCV10. Non-susceptible patterns were found to be associated with classical PCV serotypes (especially serotype 14), which is still highly prevalent, and non-PCV10 ones (19A), which may disseminate, occupying the biological niche left by the vaccine serotypes.
    International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 01/2013; 20(1). DOI:10.1016/j.ijid.2013.11.009 · 1.86 Impact Factor

  • Clinical Therapeutics 06/2013; DOI:10.1016/j.clinthera.2013.05.010 · 2.73 Impact Factor
Show more